Mark Opdam

1.2k total citations
32 papers, 570 citations indexed

About

Mark Opdam is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Mark Opdam has authored 32 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 17 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Mark Opdam's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (6 papers). Mark Opdam is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Estrogen and related hormone effects (6 papers) and HER2/EGFR in Cancer Research (6 papers). Mark Opdam collaborates with scholars based in Netherlands, Belgium and Germany. Mark Opdam's co-authors include Sabine C. Linn, Karin Beelen, P. J. van Diest, Jelle Wesseling, Joyce Sanders, Andrew Vincent, Vincent van der Noort, Tesa Severson, Michael Hauptmann and Jan B. Vermorken and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Mark Opdam

31 papers receiving 561 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Opdam Netherlands	15	278	273	201	101	84	32	570
Zhimin Shao China	11	233 0.8×	316 1.2×	234 1.2×	89 0.9×	53 0.6×	20	592
Krzysztof Fujarewicz Poland	12	388 1.4×	109 0.4×	138 0.7×	59 0.6×	57 0.7×	41	661
Eldo T. Verghese United Kingdom	15	322 1.2×	198 0.7×	258 1.3×	112 1.1×	35 0.4×	29	610
Honor J. Hugo Australia	15	520 1.9×	433 1.6×	238 1.2×	126 1.2×	83 1.0×	29	927
Maria Diez‐Rodriguez United Kingdom	17	471 1.7×	365 1.3×	383 1.9×	130 1.3×	80 1.0×	24	855
Maciej P. Zerkowski United States	8	377 1.4×	303 1.1×	184 0.9×	74 0.7×	58 0.7×	13	635
Martina Vetter Germany	14	384 1.4×	206 0.8×	341 1.7×	79 0.8×	43 0.5×	44	629
Elmar Bucher United States	10	514 1.8×	183 0.7×	205 1.0×	79 0.8×	65 0.8×	18	746
Xianyu Zhang China	17	649 2.3×	295 1.1×	307 1.5×	113 1.1×	71 0.8×	52	1.0k
Marie Wong Australia	10	479 1.7×	141 0.5×	281 1.4×	132 1.3×	167 2.0×	19	821

Countries citing papers authored by Mark Opdam

Since Specialization

Citations

This map shows the geographic impact of Mark Opdam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Opdam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Opdam more than expected).

Fields of papers citing papers by Mark Opdam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Opdam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Opdam. The network helps show where Mark Opdam may publish in the future.

Co-authorship network of co-authors of Mark Opdam

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Opdam. A scholar is included among the top collaborators of Mark Opdam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Opdam. Mark Opdam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yuwei, Annegien Broeks, Daniele Giardiello, et al.. (2023). External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer. European Journal of Cancer. 195. 113401–113401.

Liv, Nalan, Mark Opdam, Rutger C.C. Hengeveld, et al.. (2022). FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer. Cell Reports. 39(1). 110584–110584. 7 indexed citations

Stathonikos, Nikolas, et al.. (2022). Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images. Scientific Reports. 12(1). 15102–15102. 55 indexed citations

Klarenbeek, Sjoerd, Chris W. Doornebal, Sjors M. Kas, et al.. (2020). Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. OncoImmunology. 9(1). 1724049–1724049. 8 indexed citations

Opdam, Mark, Vincent van der Noort, Joyce Sanders, et al.. (2020). PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane. Journal of Cancer Research and Clinical Oncology. 146(11). 3013–3023. 6 indexed citations

Cimino‐Mathews, Ashley, Yoni Lubeck, Mark Opdam, et al.. (2020). Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. European Journal of Cancer. 127. 240–250. 18 indexed citations

Jóźwiak, Katarzyna, Heikki Joensuu, Mark Opdam, et al.. (2020). 193P Adjuvant capecitabine-containing chemotherapy is effective in both BRCA1-like and non-BRCA1-like early-stage TNBC patients. Annals of Oncology. 31. S320–S320. 1 indexed citations

Opdam, Mark, Katarzyna Jóźwiak, Michael Hauptmann, et al.. (2020). 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group. Annals of Oncology. 31. S303–S303. 16 indexed citations

Opdam, Mark, et al.. (2020). Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. Apmis. 128(4). 298–307. 6 indexed citations

10.

Sobral‐Leite, Marcelo, Mark Opdam, Karin Beelen, et al.. (2019). Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Research. 21(1). 90–90. 82 indexed citations

11.

Szíjgyártó, Zsolt, Koen D. Flach, Mark Opdam, et al.. (2019). Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES. Breast Cancer Research and Treatment. 175(1). 149–163. 3 indexed citations

12.

Kok, Marleen, Erik van Werkhoven, Mark Opdam, et al.. (2018). Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). European Journal of Cancer. 102. 40–48. 10 indexed citations

13.

Beelen, Karin, Mark Opdam, Tesa Severson, et al.. (2018). Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. BMC Cancer. 18(1). 761–761. 6 indexed citations

14.

Beelen, Karin, Mark Opdam, Joyce Sanders, et al.. (2018). Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. British Journal of Cancer. 119(7). 832–839. 18 indexed citations

15.

Droog, Marjolein, Ekaterina Nevedomskaya, Yongsoo Kim, et al.. (2016). Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas. Cancer Research. 76(13). 3773–3784. 26 indexed citations

16.

Zwart, Wilbert, Koen D. Flach, Tarek M.A. Abdel-Fatah, et al.. (2015). SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. Clinical Cancer Research. 22(2). 479–491. 14 indexed citations

17.

Schouten, Philip C., Marieke A. Vollebergh, Mark Opdam, et al.. (2015). High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1 -like Breast Cancer. Molecular Cancer Therapeutics. 15(1). 190–198. 43 indexed citations

18.

Marchi, Tommaso De, Ning Qing Liu, Mieke Timmermans, et al.. (2015). 4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Molecular Oncology. 10(1). 24–39. 32 indexed citations

19.

Beelen, Karin, Mark Opdam, Jelle Wesseling, et al.. (2014). PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. International Journal of Cancer. 135(5). 1257–1263. 26 indexed citations

20.

Beelen, Karin, Mark Opdam, Tesa Severson, et al.. (2013). CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment. 139(3). 649–655. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact